Print

APP Pharmaceuticals Announces Launch of Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP  
2/8/2012 6:52:38 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.
//-->